Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.64 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5189907 | 1.00 | PARP1 (0.64) | PARP1SMYD3PDE3BPDE3AMAOB | |
| Hydrochloric Acid SCHEMBL5189921 | 0.98 | PARP1 (0.62) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL6996227 | 0.88 | PARP1 (0.61) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL6303081 | 0.88 | PARP1 (0.80) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL6302733 | 0.88 | PARP1 (0.78) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL5967473 | 0.86 | PARP1 (0.65) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL12235342 | 0.86 | PARP1 (0.65) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL5967448 | 0.86 | PARP1 (0.65) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL6997788 | 0.85 | PARP1 (0.64) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL6999478 | 0.85 | PARP1 (0.64) | PARP1SMYD3PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-6914059-B2 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2005-07-05 | — | — | US | disclosed |
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2004-01-08 | — | — | US | disclosed |
| WO-2001081324-A1 | BENZOXAZINE DERIVATIVES AND BENZOTHIAZINE DERIVATIVES HAVING NOS-INHIBITORY AND ANTIOXIDANT PROPERTIES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | CYP4Z1, XDH, CYP3A5 | PARP1 2525/4885SMYD3 4551/4885PDE3B 4256/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | PARP1 326/4885SMYD3 1977/4885PDE3B 605/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PARP1 326/4885SMYD3 1977/4885PDE3B 605/4885 |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PARP1 156/4885SMYD3 1786/4885PDE3B 550/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PARP1 326/4885SMYD3 1977/4885PDE3B 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.